Literature DB >> 1441600

Applications of stable V79-derived cell lines expressing rat cytochromes P4501A1, 1A2, and 2B1.

J Doehmer1, C Wölfel, S Dogra, C Doehmer, A Seidel, K L Platt, F Oesch, H R Glatt.   

Abstract

1. Chinese hamster V79-derived cell lines, stably expressing cytochromes P4501A1, 1A2, and 2B1 activities, were constructed by genetic engineering in continuation of our work to establish a battery of V79 derived cell lines designed to study the metabolism of xenobiotics. 2. Cell lines XEM1 and XEM2, expressing cytochrome P4501A1, were capable of the O-dealkylation of 7-ethoxycoumarin and the hydroxylation of benzo[a]pyrene. 3. Cell lines XEMd.MZ and XEMd.NH, expressing P4501A2, were shown to hydroxylate 17 beta-estradiol and 2-aminofluorene. 4. Cell line SD1, expressing cytochrome P4502B1, was able to hydroxylate testosterone stereo- and regio-specifically at the 16 alpha and 16 beta positions. 5. Cell lines were validated in mutagenicity, cytotoxicity, and metabolism studies employing benzo[a]pyrene, trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene, cyclophosphamide, ifosfamide, and picene. 6. Construction of metabolically-competent V79-derived cell lines be recombinant DNA technology will be a fundamental improvement for the evaluation of the cytotoxic, genotoxic and pharmacological properties of a chemical.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1441600     DOI: 10.3109/00498259209051863

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Use of V79-derived cell lines expressing cytochrome P-450 activity in the study of genotoxicity of anthraquinones.

Authors:  D Fratta; S Simi; A Piras; G Rainaldi; P G Gervasi
Journal:  Cytotechnology       Date:  1993-01       Impact factor: 2.058

2.  Inhibition of cytochromes P4501A by nitric oxide.

Authors:  J Stadler; J Trockfeld; W A Schmalix; T Brill; J R Siewert; H Greim; J Doehmer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.